全文获取类型
收费全文 | 1636篇 |
免费 | 216篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 116篇 |
妇产科学 | 10篇 |
基础医学 | 267篇 |
口腔科学 | 29篇 |
临床医学 | 242篇 |
内科学 | 384篇 |
皮肤病学 | 18篇 |
神经病学 | 52篇 |
特种医学 | 274篇 |
外科学 | 161篇 |
综合类 | 23篇 |
预防医学 | 114篇 |
眼科学 | 8篇 |
药学 | 50篇 |
中国医学 | 5篇 |
肿瘤学 | 100篇 |
出版年
2023年 | 10篇 |
2021年 | 17篇 |
2020年 | 12篇 |
2019年 | 14篇 |
2018年 | 34篇 |
2017年 | 19篇 |
2016年 | 37篇 |
2015年 | 28篇 |
2014年 | 51篇 |
2013年 | 40篇 |
2012年 | 49篇 |
2011年 | 48篇 |
2010年 | 54篇 |
2009年 | 69篇 |
2008年 | 44篇 |
2007年 | 33篇 |
2006年 | 43篇 |
2005年 | 31篇 |
2004年 | 29篇 |
2003年 | 40篇 |
2002年 | 26篇 |
2001年 | 35篇 |
2000年 | 37篇 |
1999年 | 40篇 |
1998年 | 63篇 |
1997年 | 63篇 |
1996年 | 73篇 |
1995年 | 65篇 |
1994年 | 55篇 |
1993年 | 56篇 |
1992年 | 38篇 |
1991年 | 27篇 |
1990年 | 37篇 |
1989年 | 61篇 |
1988年 | 51篇 |
1987年 | 45篇 |
1986年 | 42篇 |
1985年 | 39篇 |
1984年 | 29篇 |
1983年 | 18篇 |
1982年 | 31篇 |
1981年 | 18篇 |
1980年 | 15篇 |
1979年 | 14篇 |
1977年 | 17篇 |
1976年 | 22篇 |
1975年 | 28篇 |
1972年 | 8篇 |
1970年 | 8篇 |
1966年 | 12篇 |
排序方式: 共有1859条查询结果,搜索用时 15 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
Evan S. Siegelman Eric K. Outwater Emma E. Furth Raphael Rubin 《Journal of magnetic resonance imaging : JMRI》1995,5(6):730-732
Nodular regenerative hyperplasia (NRH), a rare condition that is commonly associated with noncirrhotic portal hypertension, is not well described in the MR literature. Three patients at two institutions were identified who had both abdominal MR imaging and pathologic evidence of NRH. All examinations were performed at 1.5 T and included axial T1- and T2-weighted spin-echo (SE) images. The MR studies were reviewed by two radiologists in consensus. Two patients had multiple liver lesions that had high signal components on T1-weighted images and were predominantly isointense with liver on the T2-weighted images. One patient had no focal lesions identified. NRH, when visualized on MR images, appears as multifocal masses with shortened Tl and T2 similar to liver. NRH should be considered in the differential diagnosis of hepatocellular tumors, especially in patients with a predisposing condition. 相似文献
3.
4.
5.
6.
7.
8.
9.
10.
J W van 't Wout E R de Graeff-Meeder L C Paul W Kuis R van Furth 《Scandinavian journal of infectious diseases》1988,20(2):193-198
Two patients with cryptococcal meningitis were treated with the investigational triazole drug fluconazole (UK-49,858). Cerebrospinal fluid (CSF) levels of fluconazole were between 3.0 and 5.4 mg/l 2 h after an oral dose of 50 mg daily in the first patient and between 7.9 and 9.0 mg/l after an oral dose of 100 mg daily in the second patient. These levels were in the same range as plasma levels. The first patient, a 46-year-old renal transplant patient, was both clinically and microbiologically cured after 28 weeks of therapy (follow-up 14 months). In the second patient, a 15-year-old girl with chronic mucocutaneous candidiasis, fluconazole led to clinical cure of the meningitis, but failed to eradicate cryptococci from the CSF. These cases illustrate that fluconazole is useful for the treatment of cryptococcal meningitis, especially when prolonged treatment is indicated as in patients with immunodeficiencies. 相似文献